metabolic research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Biotechnology is a rapidly evolving field with significant potential to address pressing global challenges and improve the quality of life for people around the world; however, despite its numerous benefits, it also poses ethical and societal challenges, such as questions around genetic modification and intellectual property rights. As a result, there is ongoing debate and regulation surrounding the use and application of biotechnology in various industries and fields.
== Adrenomedullary hormones == Adrenomedullary hormones are catecholamines secreted from the adrenal medulla by chromaffin cells, neurosecretory cells connected to the central nervous system. The synthesis, storage (in chromaffin cells) and release of catecholamines is co-regulated by synaptic input from their respective pre-synaptic sympathetic neurons, as well as hormonal and local inputs. The adrenomedullary hormones are:
=== Books === 1910 Conflicts in the Child's Soul 1912 Psychology of the Unconscious 1916 Seven Sermons to the Dead (a part of the Red Book, published privately) 1921 Psychological Types 1933 Modern Man in Search of a Soul (essays) 1944 Psychology and Alchemy 1951 Aion: Researches into the Phenomenology of the Self 1952 Symbols of Transformation (revised edition of Psychology of the Unconscious) 1954 Answer to Job 1956 Mysterium Coniunctionis: An Inquiry into the Separation and Synthesis of Psychic Opposites in Alchemy 1957 The Undiscovered Self 1959 Flying Saucers: A Modern Myth of Things Seen in the Skies (Translated by R. F. C. Hull) 1960 Synchronicity: An Acausal Connecting Principle 1962 Memories, Dreams, Reflections (autobiography, co-written with Aniela Jaffé) 1964 Man and His Symbols (Jung contributed one part, his last writing before his death in 1961; the other four parts are by Marie-Louise von Franz, Joseph L. Henderson, Jaffé, and Jolande Jacobi) 2009 The Red Book: Liber Novus (manuscript produced c. 1915–1932) 2020 Black Books (private journals produced c. 1913–1932, on which the Red Book is based)
The four substrates of this enzyme are toluene, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are (1S,2R)-3-methylcyclohexa-3,5-diene-1,2-diol and reduced NAD+. This enzyme is an oxidoreductase, that uses molecular oxygen as oxidant and incorporates both its atoms into the starting material. The systematic name of this enzyme class is toluene,NADH:oxygen oxidoreductase (1,2-hydroxylating). This enzyme is also called toluene 2,3-dioxygenase. It is an iron–sulfur protein that uses flavin adenine dinucleotide as a cofactor and participates in toluene and xylene degradation.
==== Liquid forms ==== Solutions of urea and ammonium nitrate in water (UAN) are commonly used as a liquid fertilizer. In admixture, the combined solubility of ammonium nitrate and urea is so much higher than that of either component alone that it gives a stable solution with a total nitrogen content (32%) approaching that of solid ammonium nitrate (33.5%), though not, of course, that of urea itself (46%). UAN allows use of ammonium nitrate without the explosion hazard. UAN accounts for 80% of the liquid fertilizers in the US.
Sources: en.wikipedia.org
Accordingly, following critical evaluation to ensure comprehensive, quantitative analysis, new approaches can also be integrated as the critical front-end of analysis once fully vetted for their ability to resolve a full breadth of intact proteoforms inherent to proteomes, as can a variety of proteases and LC/MS/MS adaptations to ensure the highest quality peptide analyses and thus proteoform identifications
International law experts argued that the operation may have violated international law. On 3 January 2026, United Nations Spokesperson Stéphane Dujarric issued a statement that said the UN Secretary-General António Guterres was "deeply alarmed by the recent escalation in Venezuela" and that United States' military action "has potential worrying implications for the region". Lawyer Geoffrey Robertson stated that the strike on Venezuela was contrary to Article 2(4) of the UN Charter and qualifies as a crime of aggression under international law. Elvira Domínguez-Redondo, professor of international law at Kingston University, also stated the strike was an act of aggression and that it could only have been lawful if it had authorization by a United Nations Security Council resolution, or was justified as "self-defense", but she added that there was "no evidence whatsoever" to support either condition. Ben Saul, a UN special rapporteur and professor of international law, condemned "the US's illegal aggression against Venezuela and the illegal abduction of its leader and his wife" and called on Trump to be investigated and impeached. Professor of international law Michael N. Schmitt, law professor Ryan Goodman and Tess Bridgeman concluded that the operation against Venezuela "amounts to a severe breach of foundational principles of international law". Professor of law Ziyad Motala described the "intervention in Venezuela to abduct President Nicolás Maduro" as "international vandalism, plain and unadorned".
At this point, it was eagerly anticipated that such pharmacometabolomics approaches could be applied to personalized human medicine. Since this publication in 2006, the Pharmacometabolomics Research Network led by Duke University researchers and that included partnerships between centers of excellence in metabolomics, pharmacogenomics and informatics (over sixteen academic centers funded by NIGMS) has been able to illustrate for the first time the power of the pharmacometabolomics approach in informing about treatment outcomes in large clinical studies and with use of drugs that include antidepressants, statins, antihypertensives, antiplatelet therapies and antipsychotics. Totally new concepts emerged from these studies on use of pharmacometabolomics as a tool that can bring a paradigm shift in the field of pharmacology. It illustrated how pharmacometabolomics can enable a Quantitative and Systems Pharmacology approach. Pharmacometabolomics has been applied for the treatment of numerous human diseases, such as schizophrenia, diabetes, neural disease, depression and cancer.
In October 2025, Russian Foreign Ministry spokeswoman Maria Zakharova said there was no cold war with NATO because it had already developed into a "firey" conflict, and accused NATO of lying about Russian sabotage to justify vast military spending.
=== Patenting === In the U.S., efforts into creating a chimeric entity appeared to be legal when the topic first came up. Developmental biologist Stuart Newman, a professor at New York Medical College in Valhalla, N.Y., applied for a patent on a human-animal chimera in 1997 as a challenge to the U.S. Patent and Trademark Office and the U.S. Congress, motivated by his moral and scientific opposition to the notion that living things can be patented at all. Prior legal precedent had established that genetically engineered entities, in general, could be patented, even if they were based on beings occurring in nature. After a seven-year process, Newman's patent finally received a flat rejection. The legal process had created a paper trail of arguments, giving Newman what he claimed was a victory. The Washington Post ran an article on the controversy that stated that it had raised "profound questions about the differences—and similarities—between humans and other animals, and the limits of treating animals as property."
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.